Aims: To investigate factors associated with prescribing of the Extended Release Buprenorphine (XR-BUP) injectable Buvidal, and patient rated changes in outcome variables. Design: Cross-sectional an
Note: Due to missing item-level data, the sample size was less than 603. The sample size in each group is given in parentheses. a. Based on t-test or one-way ANOVA Mean and standard deviation (SD) CHL
